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A B S T R A C T
Tumor evaluation in pathology is more and more based on a combination of traditional
histopathology and molecular analysis. Due to the rapid development of new cancer treat-
ments that specifically target aberrant proteins present in tumor cells, treatment decisions
are increasingly based on the molecular features of the tumor. Not only the number of pa-
tients eligible for targeted precision medicine, but also the number of molecular targets per
patient and tumor type is rising. Diagnostic molecular pathology, the discipline that deter-
mines the molecular aberrations present in tumors for diagnostic, prognostic or predictive
purposes, is faced with true challenges. The laboratories have to meet the need of compre-
hensive molecular testing using only limited amount of tumor tissue, mostly fixed in
formalin and embedded in paraffin (FFPE), in short turnaround time. Choices must be
made for analytical methods that provide accurate, reliable and cost-effective results. Vali-
dation of the test procedures and results is essential. In addition, participation and good
performance in internal (IQA) and external quality assurance (EQA) schemes is mandatory.
In this review, we critically evaluate the validation procedure for comprehensive molecular
tests as well as the organization of quality assurance and assessment of competence of
diagnostic molecular pathology laboratories within Europe.
ª 2014 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
1. Molecular diagnostics in pathology
Routine molecular diagnostic determinations of tumor speci-
mens in the pathology laboratory have been performed since
the late 1990’s and concerned mainly classification of tumors,
clonality determinations and tests such as microsatellite
instability analysis (MSI) to select patients for referral to clin-
ical geneticists. New biological agents that target specific
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molecular alterations or act to block activated pathways pre-
sent in individual tumors have become available and enable
treatment decisions based on the molecular features of the
malignancy. This precision medicine has rapidly gained ac-
cess to daily practice and it has become a challenge for molec-
ular biologists and pathologists to provide relevant
information on the predictive markers in the shortest time-
frame possible.
In this review we will highlight aspects on choice and vali-
dation of comprehensive molecular assays including assays
using next generation sequencing (NGS) technology, and on
internal and external quality assurance of molecular tests in
Europe. Before the challenges for the molecular pathology
and validation and quality assurance issues will be discussed,
we will first give a brief overview of the different molecular
applications.
1.1. Overview of different molecular applications in
pathology
The identification of mutations or chromosomal rearrange-
ments that are characteristic for disease entities can assist
the pathologist in the differential diagnosis of these entities.
For example, fusion transcripts are seen in themajority of sar-
comas and can be, in the right pathological and clinical
context, helpful as highly specific molecular diagnostic
markers with significant impact on the classification of the tu-
mor (Bovee and Hogendoorn, 2010; Demicco, 2013). Likewise,
clonality assessment of the highly polymorphic immunoglob-
ulin and T-cell receptor gene rearrangements is an important
tool in the diagnostics of lymphomas. The clonality results
should be interpreted with knowledge of the guidelines and
the pathological and clinical context (van Krieken et al.,
2007; Groenen et al., 2012; Langerak et al., 2012). Analysis of
microsatellite instability (MSI) as a hallmark of Lynch
syndrome-associated tumors is used to select patients sus-
pected of having Lynch syndrome before referral to a clinical
geneticist. Subsequent analysis of MLH1 and MSH2 promoter
methylation is part of this diagnostics (van Lier et al., 2010),
but also somatic mutation analyses of mismatch repair genes
if no germ linemutation has been found in these patients after
referral to a clinical geneticist (Mensenkamp et al., 2014;
Geurts-Giele et al., 2014).
The identification of specificmolecular characteristicsmay
guide therapy. Genetic aberrations can discriminate if
morphological similar or asynchronous tumors in one patient
represent one or two entities or not e.g. whether a secondary
tumor is indeed an independent tumor or a metastasis of a
primary (van der Sijp et al., 2002; Blokx et al., 2007). Further-
more, analysis of the MGMT promoter methylation status in
glioblastoma has become important for predicting outcome
to treatment with temozolomide (Weller et al., 2013).
The observation that some genetic aberrations make tu-
mor cells dependent on or “addicted to” a gene product or
cellular pathway has powered the development of drugs
that specifically target these aberrations allowing treatment
based on the genetic makeup of a tumor, also called precision
medicine (Weinstein, 2002). At present there are several ge-
netic changes leading to targetable proteins. Examples are
overexpression of ErbB2 (HER2) due to ERBB2 amplification in
e.g. breast cancer, and treatment with trastuzumab (Hercep-
tin) (Piccart-Gebhart et al., 2005) and activating KIT and
PDGFRA mutations in gastrointestinal stromal tumors (GIST)
as targets for the tyrosine kinase inhibitors (TKI) (Joensuu
et al., 2001; Lasota and Miettinen, 2008). More recently, high
volume screening for EGFR and KRAS mutations and ALK,
ROS1 and RET rearrangements in non-small cell lung cancer,
KRAS and NRAS mutations in colon cancer and BRAF, NRAS
and KIT mutations in metastasized melanomas has become
an essential part of daily molecular pathology diagnostics to
select patients for targeted treatment options (Chapman
et al., 2011; Douillard et al., 2013; Lindeman et al., 2013).
2. Challenges for molecular diagnostic tests in a
pathology laboratory
The efforts of The Cancer GenomeAtlas (TCGA) initiative have
led to a still growing body of information on acquired somatic
genomic changes in different cancer genomes (Cancer
Genome Atlas Research, 2008). Due to the fast increase of
available targeted therapies as well, the TCGA efforts rapidly
result in a growing demand for routine molecular tumor diag-
nostics and screening for actionable mutations in a wide vari-
ety of tumor types. To offer patients the best treatment
options for a certain tumor, diagnostic tests should be reliable,
reproducible, of sufficient high sensitivity, and able to investi-
gate all potential targets with the constrains of limited
amount of tissue, time and budget. These criteria for compre-
hensive molecular testing require permanent development of
new assays, awareness of their potentials and drawbacks,
continuous quality assessment to improve testing of diag-
nostic tissues, consciousness of budget and costs and clinical
demands such as turnaround time. Apart from these issues
there are tissue- and technological challenges as well.
2.1. Tissue challenges
There are many challenges typically for molecular pathology
diagnostics of solid tumors. The vast majority of the DNA to
be analyzed is retrieved from routine formalin-fixed,
paraffin-embedded (FFPE) tissue, which leads to suboptimal
DNA quality for the required assays due to fixation and histo-
processing procedures (see also Groenen et al., 2011). For the
design of the molecular test it should be taken into account
that suboptimal DNA samples (isolated from routine FFPE tis-
sues) allow only amplification of small-sized PCR-amplicons
(100e200 bp). In addition, the DNA is isolated from (dissected)
tissue fragments composed of mixed populations of normal
and neoplastic cells reducing the mutant allele frequency,
and frequently only a limited amount of (biopsied) tumor tis-
sue is available containing a low percentage of neoplastic
cells, therefore the test developed must be able to accurately
detect low levels of mutations.
2.2. Technological challenges: a multitude of different
molecular tests
To detect the various genomic DNA alterations in the tumor
cells including point mutations, large insertions and
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deletions, complex indels, genomic rearrangements, MSI, and
promoter methylation, a diversity of methods has been devel-
oped for daily routine pathology molecular diagnostics. It can
be anticipated that in the era of precision medicine the num-
ber of molecular markers, which need to be assessed, will
steadily increase per sample. The challenge for the diagnostic
laboratory is to select high-performing technological method-
ologies that enable reliable detection of all mutations
requested, at a high sensitivity, with a limited amount of tis-
sue (biopsies, cytological preparations), within short turn-
around times and at low costs.
2.2.1. Mutation detection: low throughput assays
Themajority of diagnostic tests for precisionmedicine involve
awide range of PCR-based assays that amplify short DNA frag-
ments for analysis of a single gene (Bellon et al., 2011; Deans
et al., 2011; Deans et al., 2013; van den Bent et al., 2013;
Deans et al., 2014). Each of these methods has its own unique
strengths and challenges. For example, laboratory-developed
gold standard Sanger sequencing, still the method of choice
by most laboratories for detection of EGFR, KRAS, BRAF and
KIT mutations, allows detection of essentially all
diagnostically-relevant base substitutions, insertions and de-
letions, but has a relatively modest limit of detection (Tsiatis
et al., 2010; Deans et al., 2011, 2014, 2013; Wong et al., 2012).
Other commonly used methods like mutation- or allele-
specific PCR (AS-PCR), pyrosequencing, and high resolution
melting (HRM) are all considerably more sensitive, have a
faster turnaround time and less hands-on time than Sanger
sequencing. However, AS-PCR and pyrosequencing only iden-
tify mutations at predefined positions and are not suitable for
detection of novel mutations, and HRM requires often, and
pyrosequencing occasionally, confirmation by another
method (Tsiatis et al., 2010). Similarly, commercial tests like
the EGFR, KRAS and BRAF mutation tests from Roche (COBAS
test) and Qiagen (Therascreen test), have high sensitivity,
while analyzing only predefined DNA positions and are inca-
pable to detect novel mutations. In addition, commercial tests
are not flexible, since addition of tests for new actionable tar-
gets is entirely dependent on the manufacturer.
Applied technologies in molecular diagnostics should
allow fast implementation of new tests for actionable targets
to be able to offer optimal patient care. The need for this is
illustrated by the recent trial on treatment of metastatic colo-
rectal cancer, showing that besides KRAS exon 2 mutations,
another 17% of colon cancers of patients that do not respond
to anti-EGFR treatment harbor mutations in KRAS exon 3
and 4 and NRAS exon 2, 3 and 4 (Douillard et al., 2013). Impor-
tantly, when using the described low throughput assays, these
extra analyses require more material and overall costs and an
organized testing pipeline.
FDA-approved or CE-marked tests suggest a high reliability
in clinical testing. However, although the tests themselves
may be sensitive, work properly and are standardized, these
tests might not cover all clinically relevant mutations. For
example, the FDA-approved COBAS BRAF mutation test is
particularly developed for detection of BRAF p.V600E and
may also detect p.V600K and p.V600D mutations albeit less
reliable. However, in approximately 25% of the melanomas,
clinically relevant BRAF codon 600 mutations other than
p.V600E occur (da Rocha Dias et al., 2013). Using the COBAS
BRAFmutation test results in lack of detection of other codon
600 mutations, which withholds patients from appropriate
treatment. Although it can be assumed that the laboratories
are aware of these shortcomings they still can pass external
quality assessment, as long as these laboratories indicate
the shortcomings of the test in their Standard Operating Pro-
cedure (SOP). It is questionable whether this procedure should
be considered as sufficiently high quality and competent pa-
tient care.
2.2.2. Mutation detection: comprehensive analysis
None of the tests described above is suitable for high
throughput mutational analysis and may prove insufficient
to detect all clinically relevant mutations in a cost-effective
fashion in the future. For diagnostic molecular pathology,
whole genome sequencing is not yet affordable, requires too
much DNA and still has a long turnaround time. At present,
there are few options to perform comprehensive analysis for
precision medicine, including the OncoCarta panels of Biosci-
ence and targeted NGS approaches. The OncoCarta panels are
multiplexed PCR systems using a mass spectrometry-based
read-out for fast screening of more than 200 hotspotmutation
sites across 20 cancer genes. Although the method is slightly
more sensitive than Sanger sequencing and tests for more
mutations, the DNA input to obtain all this information is rela-
tively high (w500 ng), only predefined positions are screened
and detected mutations require follow-up conventional
sequencing to confirm the presence of the mutation
(Beadling et al., 2011).
NGS-based methods using the Ion Torrent Personal
Genome Machine (IT-PGM) from Life Technologies and the
MiSeq Benchtop Sequencer from Illumina are now applied
for analysis of gene-panels for diagnostic purposes (Endris
et al., 2013; Geurts-Giele et al., 2013; McCourt et al., 2013;
Tops et al., 2014). Both platforms use a sequencing-by-
synthesis approach, but the underlying sequencing technol-
ogy differs. The IT-PGM uses semiconductor sequencing
detecting hydrogen ion release during base incorporation by
DNA polymerase, the Miseq detects emission of fluorescent
signal released from labeled nucleotides after incorporation
(Ulahannan et al., 2013). The sensitivity of NGS is higher
than Sanger sequencing (detection of 2e10% versus 15e25%
allele frequency). Moreover, the amount of DNA that is needed
for the analysis of gene panels is very low, only 10e50 ng for all
amplicons (IT-PGM and Illumina, respectively) versus 10 ng
per amplicon needed for Sanger sequencing. The turnaround
time and costs can be competitive with respect to low
throughput technologies in centers that have sufficient num-
ber of samples. The use of small, dedicated gene panels and
efficient loading of the chips for IT-PGM also significantly
reduce costs per case. Both IT-PGM and MiSeq systems allow
the use of commercially established gene panels as well as
custom-designed gene panels for amplicon sequencing. The
major benefit of (targeted) NGS is that it uncovers all kinds
of mutations in selected genomic regions instead of only mu-
tations at predefined positions. An additional advantage of
NGS is that in the same assay mutations and allelic imbal-
ances can be detected e.g. EGFR amplification and loss of het-
erozygosity by single nucleotide polymorphism (SNP)
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analyses. Unfortunately, it is not yet possible to detect both
mutations and gene rearrangements in one assay by the IT-
PGM and MiSeq. Currently, a major disadvantage of NGS in
implementation in molecular diagnostics is that the data-
generating and data-processing technologies are not yet fully
developed which regularly leads to equipment and software
improvements. Below, we will further discuss these aspects
and the consequences for validation of NGS. We are most
experienced with IT-PGM analysis therefore we will further
focus on validation using this platform.
2.2.3. Detection of chromosomal rearrangements: in situ
hybridization
At present, genomic rearrangements in e.g. NSCLC are mainly
detected by in situ hybridization (ISH) on FFPE material or
cytology preparations with commercially available, CE-marked
and FDA-approved probes. The advantage of FISH is that it is
relatively fast and can be performed semi or fully automated.
However, subsequentmicroscopic analysis of the results is rela-
tively labor-intensive: it canbehard todiscriminatenormal from
tumorcells inparticular incytologypreparationsand interpreta-
tionof thesignalsmightbecomplex, especially for intrachromo-
somal rearrangements in NSCLC leading to EML4-ALK fusions
(Thunnissen et al., 2012). The number of FISH determinations
per NSCLC case increases, as apart from ALK, also ROS1 and
RET rearrangements yield actionable products. Consequently,
also thetimespent andcostsper caseexpand.Detectionofchro-
mosomal rearrangements in e.g. NSCLC might benefit from an
RNA-based sequencing approach that allows simultaneous
detectionof different chromosomal rearrangements ina limited
amount of tissue.
3. Validation of comprehensive molecular assays
Since the number of actionable mutations to be screened for
per tumor rapidly increases and the accuracy, speed and
cost enables clinical use of comprehensive molecular assays,
there is an urgent need for development of consensus valida-
tion procedures. Implementation of new technology in the
laboratory, for example NGS, needs determination of test-
conditions including DNA-input, setup of SOPs, determination
of coverage needed and testing software applications. The
desired sensitivity of the test in diagnostic samples deter-
mines the read-depth, which reflects how often a genomic re-
gion has been sequenced. In our centers, we have established
NGS assay designs resulting in a read-depth per amplicon of
500 at minimum, which enables accurate detection of low
frequency allelic variants. In general, the observed mutation
frequency will correlate with the estimated percentage of
neoplastic cells, but tumor heterogeneity may account for
the presence of low-abundance mutations. A pathologists
that is familiar with basic molecular testing should score the
percentage of neoplastic cells. The relevance for treatment
of mutations present in a low percentage of the malignant
cells due to tumor heterogeneity is not clear as yet
(Ulahannan et al., 2013).
Currently, validation occurs according to the criteria of the
local laboratory Quality Control management system and
there is no consensus for validation of NGS-tests in Europe.
In the Netherlands, modern pathology laboratories work
with specially trained clinical scientists in molecular pathol-
ogy (CSMP) who are educated in design, analysis and evalua-
tion of molecular pathology tests and have knowledge on
basic surgical pathology (see also 4.2). Also technology- and
process validation benefit from the knowledge and expertise
from these CSMPs.
Validation of broad-spectrum mutation detection requires
essentially the same process as for other conventional muta-
tional analysis i.e. addressing technology specificity by anal-
ysis of different known mutations in parallel with a “golden
standard”, for example Sanger sequencing, and assessing
sensitivity and reproducibility by replicating the analyses of
samples with different mutant allele frequencies. Commer-
cially available pre-designed reference standards might be
used especially for detection of low abundance mutations.
For example, Horizon Diagnostics (www.horizondx.com) of-
fers multiplex reference standards either purified or to be pu-
rified from FFPE cell line material to determine the limit of
detection of the used NGS system and identification of various
mutations. At least part of the NGS-method validation should
include analysis of a series of diagnostic samples, isolated ac-
cording to the standards of the laboratory, with a variety of
known mutations, comprising missense mutations, simple
and complex deletions and insertions. Representative DNA
samples from FFPE tissue are essential to include, because
DNA quality strongly affects NGS performance i.e. poor qual-
ity DNA yields higher error rate (Hofreiter et al., 2001). During
the validation process the laboratory must not only demon-
strate that the test works well but also that reliable results
are provided within the desired turnaround time.
An essential differencewith standard Sanger sequencing is
that during targeted NGS tens to hundreds amplicons are
amplified in a multiplex PCR that are subsequently simulta-
neously analyzed by massive parallel sequencing. As a conse-
quence, NGS of 50 amplicons at a read depth of 500 yields
25,000 independent sequence reads of one sample. The
complexity of one NGS analysis multiplies when simulta-
neously running multiple samples on the same chip. In this
strategy in which samples are pooled, data identification is
achieved by incorporating a sample-specific DNA barcode in
the amplified DNA fragments. Due to the enormous
complexity of these data one has to rely much more than
with Sanger sequencing on bioinformatic analysis using
appropriate software. Validation of software in the NGS-
pipeline is required, as is described by the working group of
Next-Generation Sequencing: standardization of Clinical
Testing (Gargis et al., 2012) and United Kingdom, Association
of Clinical Genetic Science Practice guidelines for Targeted
Next Generation Sequencing Analysis and Interpretation
(www.acgs.uk.com/media/774802/bpg_for_targeted_next_ge-
neration_sequencing_final.pdf). In our opinion, exchange of
raw datasets between laboratories that preferentially use
different software packages should be part of software valida-
tion in order to establish that the participating laboratories
detect identical genemutations. In addition, new software up-
dates need to be validated, by analysis of prior NGS-datasets
covering various simple and complex mutations. Finally, we
recommend the use of raw NGS datasets to become part of
in silico external assessment schemes.
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The validation process should assess the entire workflow
including the molecular report. The general information that
is needed in the report is described by van Krieken et al.
(2013a). In addition, an NGS-test report should include which
genes or regions of the genes are investigated, information
about the gene coverage, the sensitivity of the detection and
the frequency of the detected mutation. It is highly recom-
mended to evaluate themutant allele frequency in the context
of the percentage of neoplastic cells estimated by the
pathologist.
4. Quality assurance for diagnostic laboratories
Given the implications of molecular analyses on treatment of
patients a high quality of test- and laboratory performance is
required. Procedures for continuous measurement and
improvement of laboratory performance should be fully inte-
grated in the laboratory internal quality assurance system
that will ensure a consistently high standard of performance.
External quality assurance (EQA) programs, also known as
proficiency testing (PT) are inevitable for monitoring of
performance.
4.1. Internal quality assurance (IQA)
IQA is necessary to ensure high assay reproducibility and per-
formance and enable detection and correction of errors in
daily practice. Assays should be performed according to stan-
dard operating procedures (SOP) using appropriate positive
and negative controls. Implementation of new tests requires
a validation procedure using predefined parameters. Dedi-
cated trained personnel (laboratory technicians andmembers
of themedical staff) as well as amanageable, easy to use qual-
ity management system are necessary to maintain high level
of performance and improve test results or logistics whenever
needed. A laboratory quality manager is essential to take
charge of participation and performance in quality assurance
schemes and to organize internal and external audits.
4.2. Competence of personnel
IQA also involves personnel competency. The wide variety of
tests in amolecular pathology laboratory, the rapid technolog-
ical advances and high complexity of the tests requires expe-
rienced personnel. Both technicians and supervisors should
have an adequate theoretical and technical training in molec-
ular biology techniques and should remain up-to-date by
knowledge about the peer reviewed literature and by regularly
attendingmeetings and symposia. According to the guidelines
of the Dutch Society for Pathology (www.pathology.nl), each
pathology laboratory performing molecular diagnostics is
recommend to have a certified CSMP, who is responsible for
development and supervision of the molecular pathology di-
agnostics. This CSMP is a PhD or MD/PhD inmolecular biology
and/or molecular pathology and/or genetics, accomplished a
post-doctoral training in this field, and subsequently has
completed a 2-year training in molecular pathology, covering
design, analysis and evaluation of molecular tests, tissue/cell
based diagnostic possibilities and quality management. Since
2012, the Dutch Society for Pathology has officially recognized
the training program for the CSMP. We are not aware of spe-
cial requirements and training programs in other European
countries, although in France trained molecular biologists
are associated with pathologists for optimal molecular testing
(Nowak et al., 2013). In the United Kingdom there is a Royal
College of Pathologists five year Clinical Scientist specialist
training programme in Molecular Pathology of acquired dis-
ease which focuses on service delivery and development spe-
cifically for diagnosis of solid tumors within health care
science (http://www.rcpath.org/).
4.3. External quality assurance (EQA)/proficiency
testing (PT)
One of the requirements to become accredited according to
e.g. ISO 15189 is to participate in EQA programs also known
as PT, but in this paper the term EQA will be used. EQA is an
inevitable tool to periodically assess the analytical perfor-
mance of molecular tests by inter-laboratory comparison,
which will assist laboratories in monitoring their assays and
improve assay performance as well as evaluation of results
whenever needed. Frequent assessment of European labora-
tories improved the quality of EGFR mutation detection in
non-small-cell lung cancer (Deans et al., 2013), BRAF testing
of melanoma (Emile et al., 2013), and KIT mutation testing in
GIST (Wong et al., 2012). The need for EQA schemes is illus-
trated by the fact that 10e15% of laboratories do not carry
out according to the standard set by the EQA provider (van
Krieken et al., 2013b).
4.4. EQA providers in Europe
At present, there are several providers for European EQA
schemes for mutation detection in solid tumors. These
include the European Society for Pathology (ESP, www.esp-
pathology.org), and the European Molecular Genetics Quality
Network (EMQN, www.emqn.org) (Table 1). Since 2009, the
ESP offers KRAS EQA of colon cancer on a yearly basis and
the 2014 round will also include NRAS and BRAF testing
(Table 2). As of 2012, lung EQA schemes for EGFR and KRAS
mutation analysis and for detection of ALK rearrangements
by RT-PCR, ISH and via digital fluorescent ISH cases are pro-
vided. Previously, the EMQN provided EQA schemes particu-
larly for inherited disorders for laboratories worldwide. In
2014, there is also a scheme available for KRAS, NRAS and
BRAF testing in colon cancer samples.
The United Kingdom National External Quality Assess-
ment Services (UK NEQAS) for Molecular Pathology is open
for laboratories outside the UK (www.ukneqas.org.uk and
www.ukneqas-molgen.org.uk) and offers a variety of EQA
schemes, including gene panel molecular pathology EQAs
for prediction of therapy response in GISTs, lung cancer, colon
cancer and melanoma, and MSI testing (Table 2). In these EQA
schemes, the participating laboratories perform the test that
is used in the routine diagnostic setting, which can vary
from either high resolution melting, mutation-specific Taq-
Man tests, Sanger sequencing to NGS technologies for muta-
tion detection. The interpretation of the test results as well
as the evaluation of the observed genotype is described in a
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diagnostic report and presented to the EQA provider for
assessment. The EQA assessors evaluate the performance of
the participating laboratories, by scoring of: identification of
a mutation, the correct description of the genotype (coding
sequence and protein) according to the nomenclature guide-
lines of human genome variation society (www.hgvs.org),
interpretation of the observed genotype for the diagnostic
question and clerical accuracy of the report. The EQA asses-
sors produce a scheme report in which is presented: the cor-
rect genotype as scored by professional consensus,
interpretation and clinical data of the EQA-cases, an overview
of the results reported by the participating laboratories and a
critical evaluation of the observed difficulties or pitfalls, sup-
ported by references whenever needed. In our opinion,
participation in these EQA schemes is not only obligatory for
maintaining a good quality management, but also absolutely
useful, since many EQAs include at least one “difficult” case
that give laboratories insight in their performance. In addi-
tion, after introduction and validation of a newly introduced
test or technology such as NGS, participation in EQAs can be
instrumental to evaluate the performance of the new technol-
ogy on validated EQA samples.
In addition to the European EQA schemes there are na-
tional EQA schemes, among which are the Dutch Foundation
for Quality Assessment in Medical Laboratories (SKML,
www.skml.nl) andNationwide EQA in France according to rec-
ommendations of the French National Institute for Cancer
(INCa) as described in Table 2. A BRAF testing of melanoma
Table 1 e External quality assessment providers for molecular pathology schemes in Europe.
Name Abbreviation Website
European European Society for Pathology ESP www.esp-pathology.org
European Molecular Genetics Quality Network EMQN www.emqn.org
National Dutch Foundation for Quality Assessment in Medical Laboratories SKML www.skml.nl
UK National External Quality Assurance Services UK NEQAS http://www.ukneqas.org.uk
Table 2 e External quality assessment schemes for molecular pathology in Europe.
Provider Tissue Scheme Type Starting
year
European Society for Pathology Colon cancer KRAS Mutation detection 2009
Colon cancer KRAS, NRAS and BRAF Mutation detection 2014
Lung cancer EGFR, KRAS Mutation detection 2012
Lung cancer ALK Rearrangement (ISH, FISH) 2012
Lung cancer Digital ALK Rearrangement, digital cases 2012
European Molecular Genetics
Quality Network
Colon cancer KRAS, NRAS and BRAF Mutation detection 2014
UK National External Quality
Assessment Services
Adult Molecular
Neuropathology
1p/19q FISH, MGMT
promoter methylation, IDH
Translocations, methylation
and mutation detection
2012
Colon cancer KRAS Mutation detection 2009
Colon cancer KRAS, BRAF, PIK3CA and NRAS Mutation detection 2013
Gastrointestinal
stromal tumor
KIT, PDGFRA Mutation detection 2008
Lung cancer EGFR Mutation detection 2010
Lung cancer EGFR, KRAS, BRAF and PIK3CA Mutation detection 2013
Lung cancer ALK Rearrangement (ISH,
FISH, RT-PCR)
2013
Melanoma BRAF Mutation detection 2012
Melanoma BRAF, NRAS, KIT Mutation detection 2013
Sarcoma Common translocations Translocations (FISH, RT-PCR) 2014
Dutch Foundation for Quality
Assessment in Medical
Laboratoriesa
B-cell clonality IG heavy and light chain
gene rearrangements
Rearrangement detection
(Fragment analysis)
2003, 2004,
2008, 2010
Breast cancer ERBB2 (HER2) Amplification 2005, yearly
Colon cancer KRAS Mutation detection 2012
Lymphoma BCL2, BCL6 and MYC
translocations
Translocation detection 2005, 2011
Lynch prescreening MSI Fragment analysis 2006
Lung cancer EGFR, KRAS Mutation detection 2009
Lung cancer EGFR Mutation detection 2010
Melanoma BRAF Mutation detection 2012
Sarcoma Common translocations Translocations (FISH, RT-PCR) 2002 and 2009
Solid tumor clonality TP53 Mutation, LOH detection 2001
Tissue identification Polymorphic markers Fragment analysis 2002e2007
French nationwide initiative Melanoma BRAF Mutation detection 2012
a EQA schemes provided in the years indicated.
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samples EQA was a first successful nationwide effort to
improve molecular testing on FFPE tumor tissue in France
(Emile et al., 2013). The 46 French laboratories involved in mo-
lecular testing, may be stimulated by the need to become ISO
15189-accredited by 2016.
Apart for these official organizations for EQA there are “pri-
vate” initiatives to perform inter-laboratory comparisons of
molecular tests not yet being part of EQA schemes. Examples
are an international evaluation on IDH1 and IDH2 mutation
detection (van den Bent et al., 2013) and a German-Austrian-
Dutch ring test on MGMT promoter methylation (Felsberg
et al., 2013).
In conclusion, laboratories in Europe have several opportu-
nities to participate in EQA schemes. Some EQA providers, like
the UK NEQAS and the ESP, already run the same program for
several years and improve their service by increasing the
number of targets to be analyzed per tissue along with the
changes in the field. In addition, their number of molecular
programs slightly increases with time. Continuous assess-
ment with the same program is essential for laboratories to
be able to maintain and improve their competence.
5. Laboratory performance
5.1. Accreditation
In the Netherlands, accreditation of the quality system and
competence ofmedical laboratories, including (molecular) pa-
thology laboratories, is organized by an external organization
called CCKL (National Coordination Committee for Quality
Assurance for Health Care Laboratories in The Netherlands,
www.cckl.com), which since 2010 is part of the DutchNational
Accreditation Body (www.rva.nl). The CCKL guidelines are
based upon but not yet fully conform the International Orga-
nization for Standardization (ISO) 15189 norm. The national
accreditation body is now in transition towards NEN-EN-ISO
15189:2012 (www.iso.org) in order to commit to internation-
ally recognized standards. All currently CCKL-accredited labo-
ratories have to fulfill the new standard by July 2019 at the
latest. Although accreditation is strongly recommended it is
not yet mandatory, neither is the participation in EQAs.
The policy towards accreditation differs in the European
countries. For example, in Belgium only laboratories that are
accredited according to the ISO 15189 standard can get reim-
bursement, i.e. each test requires separate accreditation to
qualify for reimbursement. The Belgian laboratories are
allowed to perform unaccredited molecular test, but these
financial incentives accelerate laboratories to apply for
accreditation and thus improving their quality and compe-
tence (Raymaekers et al., 2011). In contrast, in France all med-
ical laboratories performing clinically-relevant tests are
mandatory to obtain an accreditation to the ISO 15189 stan-
dard before 2016 in order to be able to continue their clinical
activity (Nowak et al., 2012, 2013).
5.2. Actions following poor laboratory performance
EQA providers are not by themselves able to penalize labora-
tories after poor performance. In fact, solving the underlying
cause of the inferior performance is the responsibility of the
concerning laboratory. In this respect, it is of interest that
the ESP requires successful participation to be listed on their
website, thus stimulating laboratories to keep on improving
their standards. As part of this process, providers will advise
and support laboratories how to improve procedures and pro-
tocols and provide extra referencematerial (van Krieken et al.,
2013b).
Also the policy of the UK NEQAS is to encourage partici-
pants with performance difficulties to improve by education
rather than penalty. If any participant has fallen below the
acceptable performance standard, the EQA scheme director
will inform the laboratory about the poor performance status
and help and advice will be made available on request. This is
the policy for UK and non-UK participants. If a UK-laboratory
persists in poor performing (designated code red), the UK
Royal College of Pathologists National Quality Assurance
Advisory Panel (NQAAP) for Genetics will be informed with
the details of the laboratory’s performance issues. The NQAAP
will consider the best approach to improve the situation and
may arrange an urgent visit to the laboratory, review of the
service provided and offer help and advice on corrective and
preventative actions. If persistent poor performance remains
(classed as code black) the NQAAP is obliged to notify the Joint
Working Group for Quality Assessment in Pathology (JWG),
which includes the United Kingdom Accreditation Service
and Care Quality Commission (regulator of health services)
and the JWG who in turn will take further appropriate actions
tailored to the laboratory specific problems. In the end, after
several opportunities for improvement and other measures,
but remaining incapability to resolve poor performance, ac-
cording to the Genetics NQAAP-Annual Report 2011e12, the
ultimate outcomemight be closure of the laboratory. Compre-
hensive information on the NQAAP and the JWG is available
via: www.rcpath.org/committees/intercollegiate-and-joint-
committees/joint-working-group-for-quality-assessment-in-
pathology and the UK NEQAS Molecular Pathology manage-
ment procedure (www.ukneqas-molgen.org.uk/ukneqas/in-
dex/participantsManual/poorPerformanceCriteria.html).
The actions following identification of a persistent poor
performing non-UK laboratory are different. The scheme di-
rector will contact the laboratory informing them of the labo-
ratory’s persistent poor performance and offers help and
advice in order to improve the service. Should no satisfactory
response be given within a defined period, the scheme direc-
tor will discuss the situation and the suitable actions with
the Molecular Pathology Specialist Advisory Group. Experi-
ences with EQA schemes have shown that the majority of
the laboratories will correct any deficiencies before reaching
the status of a persistent poor performance laboratory.
6. Towards regional specialized centers
The use of molecular tests on tumor tissue for therapeutic de-
cisionmaking will increase and requires that the introduction
of mutation detection for new (panels of) genes in the routine
pathology practice is efficient and fast, while also providing
robust and accurate test results within a short turnaround
time (days). In order to do so, sufficient cases, personnel and
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expertise is necessary. In our opinion, it is highly unlikely that
small laboratories that have limited numbers of samples and
provide a limited number of tests can maintain their service.
Clearly, collaboration and forming regional centers for molec-
ular pathology is needed. In France, molecular pathology is
organized in 28 regional genetics centers. This network, dedi-
cated to molecular oncology tests, is initiated and funded by
the INCa and the French Ministry of Health (Nowak et al.,
2012, 2013). Nationwide organization of molecular diagnostics
including funding yields a powerful instrument to enforce ISO
15189 accreditation by all laboratories, to make it mandatory
to participate in nationwide EQA programs (Emile et al.,
2013), and to actively monitor and maintain high quality mo-
lecular diagnostics if necessary by adequate penalties in case
of poor performance. In the Netherlands, the foundation for
oncological collaboration (Stichting Oncologische Samen-
werking, SONCOS) consisting of surgical, medical and radio-
therapeutical oncologists generated a standardization report
with the minimal requirements for the treatment of different
tumor types (www.soncos.org) in 2012. There is a need for
specialized centers for treatment (and diagnostics) of
oncology patients. The ministry for health in the Netherlands
recently has decided that targeted therapies for patients with
metastasized melanoma can only be provided in a limited
number of specialized centers in the Netherlands. An impor-
tant (and wise) prerequisite is the registry of all metastasized
melanoma patients, of which clinical data, therapies, pathol-
ogy and molecular genotyping data are being registered. The
DICA (Dutch Institute for Clinical Auditing) will play an impor-
tant role in the registration and data-assessment (www.clini-
calaudit.nl). Pathology laboratories of the specialized
“Melanoma” centers need to have expertise on melanoma
and on the technologies for mutation detection of the genes
of interest (not only BRAF ).
7. Critical appraisal of laboratory performance and
quality assurance
The successful introduction of modern molecular technolo-
gies in diagnostic pathology is in our opinion regulated by
the profession of the CSMP itself, namely the requirements
for training and continuous education, as well as the
accreditation of the pathology laboratory (see also van
Krieken et al., 2010). The first guarantees the quality of the
CSMP, using their knowledge, expertise and skills to come to
optimal results and interpretation of the data. The second
guarantees that the laboratory techniques and processes are
performed standardized and yield high quality results. Suc-
cessful implementation of NGS in pathology molecular diag-
nostics clearly benefits from a close collaboration between
CSMPs and pathologists, as the latter are trained in cell/
tissue-based pathology and can provide essential information
with respect to neoplastic cells and tissue heterogeneity.
Clearly, ensuring high quality molecular testing starts
within the laboratory, with appropriately educated and dedi-
cated personnel, analyses performed by SOPs, quality
Figure 1 e Proposed model for the interaction between the EQA providers, the National Body and ISO 15189-accredited laboratories. Each
European country has an independent National body with a mandate to enforce laboratories to become ISO 15189 accredited and to participate in
EQA schemes. In case of poor performance, there will be an encouraging interaction between the EQA provider and the laboratory. In case of
persistent poor performance, the EQA provider will communicate this to the National Body who will undertake adequate steps.
Figure 2 e Proposed framework for the organization of EQA schemes
in Europe. EQA programmes are organized under supervision of the
European Society for Pathology and/or a European Quality
Assurance Council (van Krieken et al., 2008). A European
organization for the coordination of EQA schemes determines in
collaboration with representatives from the different participating
countries and the EQA providers which schemes should be provided.
One or several EQA provider(s) coordinate(s) collecting
representative tissues or in silico data and distribution of a scheme as
well as evaluation and feedback of the performance to all participating
laboratories and in case of persistent poor performance to a National
Body as depicted in Figure 1.
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assurance schemes and accreditation. IQA and EQA are essen-
tial methods to monitor the quality, performance and compe-
tence of a laboratory. To improve the current standard we
propose that all European diagnostic molecular pathology lab-
oratories are obliged to become accredited according to the in-
ternational ISO 15189 standard for medical laboratories.
Similar to the situation in the United Kingdom, we propose
that each European country has a National Body with a
mandate to enforce laboratories to become ISO 15189-
accredited and to participate in EQA schemes (Figure 1). In
case of poor performance or lack of participation the National
Body should have the authority to undertake adequate steps
and when patient care cannot be guaranteed anymore should
be able to stop funding or reimbursement and ultimately can
force the laboratory to stop clinical activity. The multiple Eu-
ropean EQA providers and the overlap in EQA schemes be-
tween providers would benefit from a structural solution to
improve efficiency: e.g. one dedicated organization that coor-
dinates all EQA schemes via one provider or via multiple
already existing providers and the EQA schemes should be
open for all European laboratories (Figure 2).
In conclusion, in our opinion molecular testing in pathol-
ogy should be performed in an ISO 15189-accredited labora-
tory that participates in EAQ schemes with a good
performance and a laboratory with appropriately educated
and dedicated personnel and with close collaboration be-
tween CSMPs and pathologists.
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